OsciPulse D-dimer Pilot Trial
NCT06477016
Recruiting
Pilot, randomized, non-blinded clinical trial to generate preliminary data to evaluate the impact of the OsciPulse system on serum d-dimer levels compared to standard of care intermittent compression therapy for DVT prophylaxis in patients admitted in the neuro ICU or intermediate neurological care unit with acute ischemic stroke.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2025
Locations: HUP Neurology Dept. of Stroke and Neurocritical Care- University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Ischemic Stroke
Register for Updates
A Modular Phase 1/2 Study with CT7439 in Participants with Solid Malignancies
NCT06600789
Recruiting
This modular, multi-part, multi-arm, Phase 1/2, FIH study allows the evaluation of the safety and tolerability of CT7439, dosed as a monotherapy and in combination with anticancer treatment in participants with solid malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2025
Locations: Research site 03, Dallas, Texas +5 locations
Conditions: Solid Malignancies
Register for Updates
Door-Through-Door Companion Rideshare Technology for Individuals with Alzheimer's Disease and Related Dementias (AD/ADRD)
NCT06850870
Recruiting
The goal of this pilot randomized controlled trial is to assess the impact of D2D rideshare services with a trained companion driver on the rate of medical appointments for older adults and individuals with AD/ADRD. Participants will be assigned either door-through-door (D2D) rideshare or curb-to-curb (C2C) rideshare services. he main question it aims to answer is: Do D2D rideshare services reduce missed medical appointment rates compared to C2C rideshare services?
Gender:
ALL
Ages:
60 years and above
Trial Updated:
02/24/2025
Locations: Onward Health HQ, San Leandro, California
Conditions: Alzheimer Disease or Associated Disorder, Dementia, Cognitive Decline
Register for Updates
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
NCT03907046
Recruiting
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2025
Locations: University of Alabama Hospital, Birmingham, Alabama +169 locations
Conditions: Intracerebral Hemorrhage, Atrial Fibrillation
Register for Updates
Atorvastatin ± Aspirin in Lynch Syndrome Syndrome
NCT04379999
Recruiting
The goal of this study is to investigate that a common cholesterol lowering agent (atorvastatin) alone or combining with a nonsteroidal anti-inflammatory drug (aspirin) would reduce the risk of colorectal cancer (CRC) in high-risk individuals with Lynch syndrome.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/24/2025
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Lynch Syndrome
Register for Updates
TBI Evaluation and Management (TEaM)
NCT04576715
Recruiting
The purpose of this study is to evaluate a multi-disciplinary, multi-setting intervention with the goal of improving outcomes for children who have experienced a mild traumatic brain injury (mTBI). The project aims to improve and support mTBI diagnosis and management, and improve critical decision making by clinicians during their interaction with the injured child, their family, and their school.
Gender:
ALL
Ages:
5 years and above
Trial Updated:
02/24/2025
Locations: Children's Healthcare of Atlanta (CHOA) - Egleston Emergency Department, Atlanta, Georgia +2 locations
Conditions: Mild Traumatic Brain Injury
Register for Updates
US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies
NCT04990323
Recruiting
Cord blood (CB) transplants are an option for patients lacking an HLA identical donor but are hampered by low cell dose, prolonged aplasia and high transplant related mortality. UM171, a novel and potent agonist of hematopoietic stem cell self renewal could solve this major limitation, allowing for CB's important qualities as lower risk of chronic GVHD and relapse to prevail. In previous trials (NCT02668315, NCT03913026, NCT04103879, and NCT03441958), the CB expansion protocol using the ECT-001-... Read More
Gender:
ALL
Ages:
Between 0 years and 21 years
Trial Updated:
02/24/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: High Risk Myeloid Malignancies, Cord Blood Transplant
Register for Updates
Enfortumab Vedotin and Pembrolizumab in People with Bladder Cancer
NCT05239624
Recruiting
This study will test whether enfortumab vedotin combined with pembrolizumab is an effective treatment for people with bladder cancer (urothelial carcinoma) involving the lymph nodes who are going to have surgery to remove their cancer (cystectomy). The researchers will look at whether treatment with enfortumab vedotin and pembrolizumab before surgery can get rid of cancer within the lymph nodes. They will also try to find out if this combination of drugs is effective at shrinking participants' c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2025
Locations: Baptist Alliance MCI, Miami, Florida +9 locations
Conditions: Urothelial Carcinoma
Register for Updates
FitMi AD Home Therapy for Individuals with MCI or Mild Dementia Due to Alzheimer's Disease
NCT05504811
Recruiting
This study will investigate the efficacy of a newly developed exercise device (FitMi AD) for individuals with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease. FitMi AD uses embedded sensors that can track and record the patient's direction and degree of movement while performing exercises described on a computer.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
02/24/2025
Locations: Rancho Research Institute, Inc, Downey, California
Conditions: Cognitive Dysfunction, Dementia, Mild
Register for Updates
Brain Structure and Clinical Endpoints in Myotonic Dystrophy Type 2
NCT05854433
Recruiting
Nearly two-third of patients with myotonic dystrophy type 2 (DM2) report that impaired cognition is among the most disabling symptoms and deeply affects their quality of life. Yet, relatively little is known about how DM2 affects brain structure and cognitive function as brain imaging studies in DM2 are extremely limited. This is a prospective, cross-sectional study of brain structure and function on cognitive and motor performance in patients with DM2 compared to healthy controls. All participa... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
02/24/2025
Locations: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Conditions: Myotonic Dystrophy Type 2
Register for Updates
18F-FLUC-CEST PET/MR in Patients With Brain Mets
NCT06159335
Recruiting
The goal of this clinical trial is to use new imaging methods to help in finding out whether the imaging shows that there is a tumor in people with a brain metastasis. The main question it aims to answer is whether positron emission tomography (PET) and magnetic resonance imaging (MRI) find cancerous tissue better than other types of imagining. Participants will undergo a single PET/MRI scan, followed by a separate MRI scan with a tracer. Study participation will last about 3 hours.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Brain Metastasis, Radiation Therapy, Immunotherapy, Active
Register for Updates
A Study of Pitolisant in Patients with Prader-Willi Syndrome
NCT06366464
Recruiting
This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, global clinical study to assess the efficacy and safety of pitolisant in patients living with Prader-Willi syndrome. The primary objective of this study is to evaluate the efficacy of pitolisant in treating excessive daytime sleepiness (EDS) in patients ≥6 years of age with Prader-Willi syndrome. Secondary objectives include assessing the impact of pitolisant on: * Irritable and disruptive behaviors * Hyperphagia *... Read More
Gender:
ALL
Ages:
6 years and above
Trial Updated:
02/24/2025
Locations: Santa Monica Clinical Trials, Los Angeles, California +21 locations
Conditions: Prader-Willi Syndrome
Register for Updates